KROS
Price
$11.36
Change
+$0.10 (+0.89%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
223.65M
40 days until earnings call
Intraday BUY SELL Signals
MNPR
Price
$78.07
Change
+$0.10 (+0.13%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
561.94M
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KROS vs MNPR

KROS vs MNPR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KROS vs. MNPR commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KROS is a Hold and MNPR is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
KROS vs MNPR: Fundamental Ratings
KROS
MNPR
OUTLOOK RATING
1..100
7452
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
37
Fair valued
PROFIT vs RISK RATING
1..100
10046
SMR RATING
1..100
9495
PRICE GROWTH RATING
1..100
5661
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
49n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNPR's Valuation (37) in the null industry is in the same range as KROS (50). This means that MNPR’s stock grew similarly to KROS’s over the last 12 months.

MNPR's Profit vs Risk Rating (46) in the null industry is somewhat better than the same rating for KROS (100). This means that MNPR’s stock grew somewhat faster than KROS’s over the last 12 months.

KROS's SMR Rating (94) in the null industry is in the same range as MNPR (95). This means that KROS’s stock grew similarly to MNPR’s over the last 12 months.

KROS's Price Growth Rating (56) in the null industry is in the same range as MNPR (61). This means that KROS’s stock grew similarly to MNPR’s over the last 12 months.

KROS's P/E Growth Rating (100) in the null industry is in the same range as MNPR (100). This means that KROS’s stock grew similarly to MNPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KROSMNPR
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (KROS: $11.26 vs. MNPR: $77.97)
Brand notoriety: KROS and MNPR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KROS: 62% vs. MNPR: 73%
Market capitalization -- KROS: $223.65M vs. MNPR: $561.94M
KROS [@Biotechnology] is valued at $223.65M. MNPR’s [@Biotechnology] market capitalization is $561.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KROS’s FA Score shows that 0 FA rating(s) are green while MNPR’s FA Score has 0 green FA rating(s).

  • KROS’s FA Score: 0 green, 5 red.
  • MNPR’s FA Score: 0 green, 5 red.
According to our system of comparison, MNPR is a better buy in the long-term than KROS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KROS’s TA Score shows that 3 TA indicator(s) are bullish while MNPR’s TA Score has 3 bullish TA indicator(s).

  • KROS’s TA Score: 3 bullish, 5 bearish.
  • MNPR’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both KROS and MNPR are a bad buy in the short-term.

Price Growth

KROS (@Biotechnology) experienced а -2.51% price change this week, while MNPR (@Biotechnology) price change was -12.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

KROS is expected to report earnings on Nov 11, 2026.

MNPR is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
KROS
Daily Signal:
Gain/Loss:
MNPR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QSPT36.610.06
+0.16%
FT Vest Nasdaq-100 Buffer ETF - September (QSPT)
HIDV88.91N/A
N/A
AB US High Dividend ETF (HIDV)
LTCC10.88N/A
N/A
Canary Litecoin ETF
DDFF20.35N/A
-0.02%
Innovator Equity Dual Directional 15 Buffer ETF - February (DDFF)
SCHZ22.07-0.03
-0.14%
Schwab US Aggregate Bond ETF (SCHZ)

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
-1.23%
AXON - KROS
43%
Loosely correlated
-0.07%
ABEO - KROS
43%
Loosely correlated
-4.57%
EYPT - KROS
43%
Loosely correlated
-1.22%
IMVT - KROS
42%
Loosely correlated
-0.38%
SANA - KROS
40%
Loosely correlated
-0.86%
More